P/B
11,8
DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
$29.8B
Market Cap • 11/10/2026
1999
(27 years)
Founded
2005
(21 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
5,8
P/EBITDA
19,9
P/OCF
21,1
P/FCF
27,1
P/E
31,3
BVPS
6,8
EPS
2,5
Market Cap
Market Cap
29,8B
EV
29,3B
EV/Revenue
5,7
EV/EBITDA
19,6
EV/EBIT
24
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
4,3%
Total Yield
4,3%
Payout
0%
Retained Earnings
3,2B
Profitability
Gross Margin
63,4%
EBITDA Margin
29,4%
EBIT Margin
24%
Net Margin
19,4%
D&A/EBITDA
0%
R&D/Revenue
11,9%
Capex/Revenue
6,2%
Capex/D&A
114,9%
Capex/OCF
22,3%
SBC/OCF
10,9%
% PPE
26,1%
% Goodwill
0,4%
ROE
37,7%
ROIC
32,8%
Growth
CAGR Revenue 5Y
17,1%
CAGR Op. Income 5Y
27,1%
CAGR Net Income 5Y
9,4%
CAGR EPS 5Y
12,6%
CAGR OCF 5Y
22,7%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
1,7
Quick Ratio
1,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!